Platelet-Related Biomarkers and Efficacy of Antiplatelet Therapy in Patients with Aortic Stenosis and Coronary Artery Disease
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26157083 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Paweł Bańka und 7 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, 40-635 Katowice, Poland. Hauptthemen laut MEDLINE: Biomarkers, Platelet Aggregation Inhibitors, Coronary Artery Disease, Aortic Valve Stenosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Silesia.
Abstract (Originalsprache)
The objective of this study was to evaluate the serum biomarkers implicated in the interaction of platelets and endothelium, as well as the efficacy of antiplatelet therapy in patients with aortic stenosis (AS) and coronary artery disease (CAD). A total of 78 adult patients with CAD on aspirin therapy participated in this study, including 49 consecutive patients with AS and 29 control subjects. The analysis included the following serum biomarkers: thrombomodulin (TM), platelet factor 4 (PF4), P-selectin, and CD40L. The efficacy of antiplatelet treatment was evaluated using the VerifyNow Aspirin test (ASPI test) and P2Y12 assay test (ADP test). Patients with AS exhibited increased serum levels of TM (7.64 ± 3.5 ng/mL vs. 6.28 ± 2.1 ng/mL, p = 0.011) and PF4 (25.16; Q1: 8.3; Q3: 29.6 μg/mL vs. 12.85; Q1: 5.7; Q3: 14.5 μg/mL, p = 0.021) compared to the control group. P-selectin and CD40L levels did not differ between groups. There were no significant differences in platelet aggregation in the ASPI (474.04 ± 66.7 ARU vs. 471.31 ± 56.2 ARU; p = 0.822) or ADP (224.88 ± 46.4 PRU vs. 216.62 ± 29.6 PRU; p = 0.394) tests. Bleeding incidence did not differ significantly between groups. The coexistence of AS in patients with CAD is associated with elevated levels of the aforementioned biomarkers, which are indicative of endothelial damage and platelet activation. However, the efficacy of antiplatelet treatment was independent of the presence of AS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, 40-635 Katowice, Poland.
- Centre of the European Reference Network for Rare, Low Prevalence or Complex Diseases of the Heart (ERN GUARD Heart), 40-635 Katowice, Poland.
- Department of Biochemistry, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland.
ORCID-Profile: Maciej Podolski, Agnieszka Kosowska, Wojciech Garczorz, Tomasz Francuz, Maciej Wybraniec, Katarzyna Mizia-Stec
Förderung
- Medical University of Silesia
Zitieren
APA
Bańka, P., Czepczor, K., Podolski, M., Kosowska, A., Garczorz, W., Francuz, T., Wybraniec, M., & Mizia-Stec, K. (2025). Platelet-Related Biomarkers and Efficacy of Antiplatelet Therapy in Patients with Aortic Stenosis and Coronary Artery Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157083
Vancouver
Bańka P, Czepczor K, Podolski M, Kosowska A, Garczorz W, Francuz T, et al. Platelet-Related Biomarkers and Efficacy of Antiplatelet Therapy in Patients with Aortic Stenosis and Coronary Artery Disease. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157083
BibTeX
@article{Baka2025,
author = {Bańka, Paweł and Czepczor, Kinga and Podolski, Maciej and Kosowska, Agnieszka and Garczorz, Wojciech and Francuz, Tomasz and Wybraniec, Maciej and Mizia-Stec, Katarzyna},
title = {Platelet-Related Biomarkers and Efficacy of Antiplatelet Therapy in Patients with Aortic Stenosis and Coronary Artery Disease},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26157083}
}
EUVIMED